The first study, currently open and recruiting participants, is a Phase 2 study of a vaccine (GI-6207) in patients with recurrent Medullary Thyroid Cancer (MTC). The goal of this study is to get the individual’s immune system to respond to the vaccine by making immune cells that can recognize and attach tumor cells. Patients involved with this study will receive up to one year of treatment. Interested? Click here to learn more.
The second study, which will open in about two months, focuses on Ponatinib for advanced MTC. The primary objective of this study is to observe the overall response rate to Ponatinib in the treatment of three types of patients:
- Patients with advanced metastatic MTC who have tumors with RET mutations and have been previously treated with a RET inhibitor.
- Patients who have tumors with RET mutations and have not been previously treated with a RET inhibitor.
- Patients who have tumors without RET mutations, whether or not they have received a prior RET inhibitor.
If you would like more information about this trial, click here.